Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · May 23, 2024

Safety of Next-Generation Oral SERD Camizestrant as Monotherapy in ER+/HER2− Advanced Breast Cancer

Annals of Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

Annals of Oncology
A Phase 1 dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results
Ann. Oncol 2024 May 08;[EPub Ahead of Print], E Hamilton, M Oliveira, N Turner, J García-Corbacho, C Hernando, EM Ciruelos, P Kabos, MR Borrego, A Armstrong, MR Patel, C Vaklavas, C Twelves, V Boni, J Incorvati, T Brier, L Gibbons, T Klinowska, JPO Lindemann, CJ Morrow, A Sykes, R Baird

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading